Astria Therapeutics Announces Positive Initial Results from Long-Term Navenibart Trial in HAE Patients
Astria Therapeutics Inc. (NASDAQ:ATXS) is one of the stocks under $10 to buy now.
Astria Therapeutics Inc. (ATXS)
This company is not actively trading or the ticker does belong to another company in our database now.
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Birnam Oak Advisors Christopher Delong | 0 | $0 | 0% | |
| 2. | Alpine Associates Robert Emil Zoellner | 0 | $0 | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $12.09 | 2,481,350 | $29,999,521.50 | 4,873,721 | 2024-02-01 | Filing | |
| $6.20 | 740,000 | $4,588,000.00 | 2,392,371 | 2023-12-21 | Filing | |
| $6.51 | 460,546 | $2,999,996.64 | 1,611,699 | 2023-10-16 | Filing | |
| $6.51 | 614,062 | $3,999,999.87 | 1,652,371 | 2023-10-16 | Filing | |
| $11.01 | 908,265 | $9,999,997.65 | 1,038,309 | 2022-12-19 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $13.59 | 10,000 | $135,939.00 | 0 | 2024-04-01 | Filing | |
| $11.15 | 9,200 | $102,552.40 | 0 | 2024-01-29 | Filing | |
| $11.02 | 800 | $8,812.00 | 0 | 2024-01-26 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 0 | $0 | 0% | |
| 2. | 0 | $0 | 0% | |
| 3. | 0 | $0 | 0% | |
| 4. | 0 | $0 | 0% | |
| 5. | 0 | $0 | 0% |
News See All
10 Stocks Under $10 to Buy Now
Earlier on July 1, Peter Kraus, Aperture Investors chairman and CEO, joined 'Squawk Box' on CNBC to suggest that the small and mid-cap area is a place for significant growth.
10 Low Risk High Reward Stocks Set to Triple by 2030
The market is getting tough these days with increasing interest rates, tense world politics, and inconsistent economic conditions, and investors are constantly looking for opportunities.
14 Stocks With Heavy Insider Buying In 2024
Markets await latest inflation numbers and the debate regarding soft vs hard landing is expected to persist in the Wall Street for months to come.
Astria Therapeutics, Inc. (NASDAQ:ATXS) Q3 2023 Earnings Call Transcript
Operator: Good morning and welcome to the Astria Therapeutics Quarter Three 2023 Corporate Update. At this time, all attendees are in a listen-only mode.
Astria Therapeutics, Inc. (NASDAQ:ATXS) Q4 2022 Earnings Call Transcript
Operator: Good morning and welcome to the Astria Therapeutics 2022 Q4 and Full Year Financial Results and Business Update Conference Call. At this time, all attendees are in a listen-only mode.
12 Best Performing Biotech Stocks in 2022
Fitch Ratings has assigned a Neutral rating to the global pharmaceutical and biotech industry, which indicates the assumption of a collaborative operating backdrop in 2023, although inflationary pressures...
Hedge Fund and Insider Trading News: Cathie Wood, Karthik Sarma, D.E. Shaw, Alameda Research, Astria Therapeutics, Inc. (ATXS), Dave & Buster's Entertainment, Inc. (PLAY), and More
Cathie Wood’s ARK Innovation Fund, which more than doubled during the pandemic rally, is on pace to finish near the very bottom of all U.S.
10 Best Immunology Stocks to Invest In
Immunology is the study of the immune system of higher organisms in relation to disease.
Hedge Fund Resource Center